The effect of the long-acting somatostatin analogue SMS 201-995 on ACTH secretion in Nelson's syndrome and Cushing's disease.
Chronic therapy of a patient with Nelson's syndrome for 2 years with 300 micrograms SMS 201-995 per day resulted in a significant decrease in circulating ACTH levels, normalization of the visual field defect and of loss of visual acuity of one eye, and stabilization of tumour growth, without radiological evidence of shrinkage of the pituitary tumour. In two other patients with Nelson's syndrome, SMS 201-995 acutely inhibited circulating ACTH levels. This effect could be shown best if cortisol replacement was temporarily withheld. SMS 201-995 did not affect plasma ACTH and cortisol levels in three patients with untreated Cushing's disease.
Lamberts
S W
SW
Department of Medicine, Erasmus University, Rotterdam, The Netherlands.
Uitterlinden
P
P
Klijn
J M
JM
D000324:Adrenocorticotropic Hormone / Q000378:metabolism*; D000328:Adult; D002986:Clinical Trials as Topic; D003480:Cushing Syndrome / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D008297:Male; D009347:Nelson Syndrome / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D015282:Octreotide / Q000008:administration & dosage*; D010911:Pituitary Neoplasms / Q000188:drug therapy*; D013997:Time Factors; D014792:Visual Acuity / Q000187:drug effects
D003692:Delayed-Action Preparations; D000324:Adrenocorticotropic Hormone; D015282:Octreotide